MicroRNAs (miRs) are mRNA-regulatory molecules that fine-tune gene expression and modulate both processes of development and tumorigenesis. Our previous studies identified progranulin A (GrnA) as a growth factor which induces zebrafish hepatic outgrowth through MET signaling. We also found that miR-145 is one of potential fine-tuning regulators of GrnA involved in embryonic hepatic outgrowth. The low level of miR-145 seen in hepatocarinogenesis has been shown to promote pathological liver growth. However, little is known about the regulatory mechanism of miR-145 in embryonic liver development. In this study, we demonstrate a significant decrease in miR-145 expression during hepatogenesis. We modulate miR-145 expression in zebrafish embryos by injection with a miR-145 mimic or a miR-145 hairpin inhibitor. Altered embryonic liver outgrowth is observed in response to miR-145 expression modulation. We also confirm a critical role of miR-145 in hepatic outgrowth by using whole-mount in situ hybridization. Loss of miR-145 expression in embryos results in hepatic cell proliferation, and vice versa. Furthermore, we demonstrate that GrnA is a target of miR-145 and GrnA-induced MET signaling is also regulated by miR-145 as determined by luciferase reporter assay and gene expression analysis, respectively. In addition, co-injection of GrnA mRNA with miR-145 mimic or MO-GrnA with miR-145 inhibitor restores the liver defects caused by dysregulation of miR-145 expression. In conclusion, our findings suggest an important role of miR-145 in regulating GrnA-dependent hepatic outgrowth in zebrafish embryonic development.
Introduction
The liver is the largest metabolic organ that maintains numerous vital functions in the body. The liver is composed of approximately 80% hepatocytes and other cell types, including cholangiocytes, Kupffer cells, stellate cells and sinusoidal endothelial cells [1] . Liver development is divided into three stages beginning with specification in the foregut endoderm and followed a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 recirculation systems (~28˚C water, pH 7.5-8) in 2-litre aquaria under a 14h:10h light-dark cycle and fed twice daily. The embryos were collected using natural mating and transferred to Petri dishes filled with E3 medium (287 mg/l NaCl, 13 mg/l KCl, 48 mg/l CaCl 2 , 81 mg/l MgCl 2 , 3 ml 0.01% (w/v) methylene blue, in dH 2 O). The embryos and larvae were kept in an incubator set at 28˚C under a 14h:10h light-dark period [24] . To prevent pigmentation, the embryos were treated with 0,003% PTU at 24 hpf [25] . In all zebrafish embryo experiments, tricaine methanesulfonate (MS-222) (0.168 mg/ml) was used as a zebrafish anesthetic agent. Overdose of MS-222 (200-300 mg/l) was used for zebrafish euthanasia. The animal protocols used in this study had been evaluated and approved by the Institutional Animal Care and Use Committee of Academia Sinica (AS IACUC), Taiwan.
miRNAs prediction on zebrafish GrnA
Computer-based programs were used to predict potential miRNAs targeting zebrafish GrnA. From miRNAs prediction of GrnA, miR-9, miR-206, miR-731, and miR-217 on 3' UTR were predicted by TargetScan (http://www.targetscan.org/). The miR-145 on GrnA CDS region was predicted by MicroInspector [26] and RNAhybrid [27] .
MicroRNA mimic, inhibitor injection and rescue assay
The 3 ng/embryo of control mimic (5'-UCACAACCUCCUAGAAAGAGUAGA-3'), 1.5 and 3 ng/embryo miR-145 mimic (5'-GUCCAGUUUUCCCAGGAAUCCCU-3'), 3 ng/embryo miR-9 mimic (5'-UCUUUGGUUAUCUAGCUGUAUGA-3'), 0.03ng/embryo miR-206 mimic (5 0 -UGG AAUGUAAGGAAGUGUGUGG-3'), 3 ng/embryo miR-731 mimic (5'-AAUGACACGUUUUCU CCCGGAUCG-3'), 3 ng/embryo miR-217 mimic (5'-UACUGCAUCAGGAACUGAUUGG-3') and 1.5 and 3 ng/embryo miR-145 inhibitor (Dharmacon, Thermo) were injected into onecell stage embryos. The miR-145 inhibitor is 2 0 -O-methyl antisense oligonucleotides that against miR-145 were synthesized by Dharmacon RNA Technologies. Zebrafish GrnA (0.1, 0.2 and 0.4 ng/embryo) mRNA was synthesized using the mMESSAGE mMACHINE kit (Ambion, USA) and grnA morpholino (0.0625, 0.125 and 0.25 ng/embryo) (Gene Tools, USA). These were co-injected with miR-145 mimic or inhibitor for the rescue assay.
Cell culture and transfection
ZFL cells (ATCC Number: CRL-2643) from zebrafish normal liver tissue were cultured in Leibovitz's L-15 medium containing 50% 2 mM L-glutamine (Vitacell , 35% Dulbecco's Modified Eagle's medium (GIBCO12100), and 15% Ham's F12 (GIBCO 21700), which was supplemented with 5% fetal bovine serum, 0.15 g/L sodium bicarbonate, 15 mM HEPES, 0.01 mg/ml insulin, 50 ng/ml EGF and penicillin/streptomycin (Invitrogen). miR-145 mimic, miR-145 hairpin inhibitor and negative-control mimic were purchased from Dharmacon (Thermo). The day before transfection, the cells were seeded in antibiotic-free medium. Transfections of plasmids and RNA duplexes were carried out using LipofectamineTM 2000 in accordance with the manufacturer's guidelines (Invitrogen).
Construction of reporter plasmids for luciferase assays
The predicted target sequences of GrnA were cloned downstream of the renilla luciferase gene (XhoI/NotI sites) in the psiCheck-2 plasmid (Promega) and designated the psi-Grna vector. The predicted target sequences of grnA were (5' to 3'): forward TCGAGTCAGCCGGAGACTTGGACTG GAGCAACTGGGTCAACTGGAAGC, reverse CAGTCGGCCTCTGAACCTGACCTCGTTGACCCAGTT GACCTTCGCCGG. ZFL cells (~5×10 5 control mimic (50 nM) and target reporter plasmid (1.6 μg) using LipofectamineTM 2000 (Invitrogen). The transfections and luciferase activity measurements were carried out using the Invitrogen LipofectamineTM 2000 / Promega Dual-luciferase kit according to the manufacturer's instructions. The relative renilla activity was assessed as renilla/firefly luciferase ratios.
Immunohistochemistry and whole-mount in situ hybridization
For immunohistochemistry, fixed and paraffin-embedded embryos were sectioned and hybridized with a PCNA antibody (PC10; Abcam, UK) and using an In situ Cell Death Detection Kit, POD (Roche, Germany). For whole-mount in situ hybridization (WISH), digoxigenin (DIG)-labeled or fluorescein-labeled antisense RNA probes for grna (NM_001001949), hhex (NM_130934), sePb (XM_001923882), prox1 (NM_131405) and fabp10 (NM_152960) were generated by in vitro transcription using T7 or SP6 RNA polymerase. miR-145 5' and 3' DIGlabeled LNA probes (Exiqon) were used for miRNA in situ hybridization. Confocal images were obtained using a Leica SP5 confocal microscope and were analyzed using Imaris software.
Real-time quantitative RT-PCR
The expression levels of miR-145, GrnA and MET signaling were measured in zebrafish embryos treated with control, miR-145 mimic or miR-145 hairpin inhibitor using a High Capacity cDNA Reverse Transcription kit and Power SYBR Green PCR master Mix (Applied Biosystems). Total RNAs were extracted from each sample with TRIzol reagent (Invitrogen). The reverse transcription reaction was performed with 1 μg of total RNA. Real-time PCR was performed using a LightCycler 480 Real-time PCR system (Roche) according to the manufacturer's instructions. The levels of U6 RNA and ef1a mRNA were used to normalize the relative miRNA and mRNA abundance.
Western blots and antibodies
ZFL cells were transfected in six-well plates with miR-145 mimic (final concentration 100 nM), miR-145 hairpin inhibitor (final concentration 100 nM) or miR-control (final concentration 100 nM). After transfection, cells were cultured for 48 hours. Intermediate samples were collected and analyzed by western blot to assess GrnA and MET expression. The lysates were hybridized with the following primary antibodies: the polyclonal anti-GrnA antibody (1:1000), which was produced using the 4MAPS peptide EWEDHKQKKPETQRTTTRPTG (corresponding to residues 244-264 of GrnA) to immunize BALB/c mice (LTK Biolab Incorporation, Taiwan); Met antibody (1:1000, sc-10; Santa Cruz Biotechnologies, USA); and GAPDH antibody (1:1000; AnaSpec, USA).
Imaging
All 2-dimensional images were captured using Zeiss SV-11 APO Microscope and SPOT RT3 color digital camera and analyzed by SPOT image software. The liver size was quantified by measuring the fluorescence intensity in 3-dimensional images using Leica SP5 confocal microscope and analyzed by Imaris software.
Statistical analysis
Twenty, 30 or 100 embryos (from one clutch) per experimental group were used. Three independent replicates were performed. Data were presented as mean ± SEM (standard error of mean). Two-tailed unpaired Student's t-test was used to determine the significance of differences between groups ( Ã P 0.05; ÃÃ P 0.01). Results miR-145 is one of miRNAs prediction on zebrafish GrnA that affects embryonic liver growth
To identify the fine-tuning regulator of GrnA-mediated MET signaling, we identified several microRNAs (miRNAs) from the miRNA predictions of GrnA using bioinformatics software. The miRNA predictions of GrnA included miR-9, miR-206, miR-731, miR-217 on 3'UTR and miR-145 on CDS region (Fig 1A) . Liver morphology at 4 dpf was observed after injecting control mimic, miR-145 mimic, miR-9 mimic, miR-206 mimic, miR-731 mimic and miR-217 mimic in Tg(fabp10:EGFP) embryos. The liver size was examined by measuring the volume of EGFP expression in 3-dimension confocal images. The EGFP expression of Tg (fabp10:EGFP) fish showed no significantly changes in liver size in miR-9 mimic-, miR-206 mimic-, miR-731 mimic-and miR-217 mimic-injected fish, but the miR-145 mimic-injected fish has a smaller liver size (Fig 1B) . The liver volume in miR-145 mimic-injected fish was estimated to be 0.47± 0.07×10 (Fig 1C) . These findings suggest that only miR-145 can affect embryonic liver growth among the predicted miRNAs of GrnA.
miR-145 and GrnA expression patterns are inversely correlated during liver development Fluorescence in situ hybridization (FISH) was used to determine the miR-145 and GrnA expression patterns specifically in liver development. Fluorescence-labeled RNA probes of the hepatoblast-specific marker prospero-related homeobox 1 (prox1) and DIG-labeled miR-145 or GrnA RNA probes were detected at 30, 50, 72 and 96 hpf in wild-type (AB) zebrafish embryos. miR-145 was expressed in hepatoblasts at 30 and 50 hpf but decreased at 72 and 96 hpf (Fig 2A) . In contrast, GrnA expression increased from 30 to 96 hpf (Fig 2B) . To analyze the liver specific expression pattern of miR-145 and GrnA, we isolated the fetal liver at 72 and 96 hpf to perform qPCR. The qPCR result reveals that the expression of miR-145 in embryonic liver at 96 hpf decreased as compared to that at 72 hpf. Inversely, the expression of GrnA in embryonic liver at 96 hpf increased as compared to that at 72 hpf ( Fig 2C) . These results indicate that miR-145 and GrnA expression are inversely correlated during liver development.
miR-145 expression level negatively regulates embryonic liver size
To study the regulatory mechanism of miR-145 in embryonic liver development, we blocked the mature miR-145 function using a miR-145 hairpin inhibitor and enhanced miR-145 expression using a miR-145 RNA mimic. To control for the specificity of the miR-145 mimic and inhibitor, a negative control mimic was used, the sequence of which was based on C. elegans microRNAs that have minimal sequence identity to zebrafish. A total of 3 ng of control, miR-145 inhibitor or miR-145 mimic was injected into wild-type zebrafish embryos. In situ hybridization using an LNA antisense probe against mature miR-145 indicated that the miR-145 inhibitor reduced the level of miR-145 (S1C and S1D Fig) and miR-145 mimic treatment increased miR-145 expression (S1E and S1F Fig) compared to that seen in control mimicinjected fish at 72 hpf (S1A and S1B Fig) . In addition, quantitative real-time PCR (qPCR) of miR-145 showed that apparent miR-145 was significantly decreased after miR-145 inhibitor injection and that apparent miR-145 expression was increased approximately thirty fold after miR-145 mimic injection (S1G Fig). To test the specificity, we determined the expression level of Gata6, which is a known target of miR-145 [28] , in miR-145 mimic-and inhibitor-injected fish. The expression level of Gata6 showed a 2.4-fold increase in miR-145 inhibitor-injected EGFP) fish showed a smaller liver phenotype in miR-145 mimic-treated fish compared to wild type, control fish and other miRNAs mimic-treated fish. Thirty embryos per experimental group from one clutch were used and three independent replicates were performed. (C) A 3D image of the liver was analyzed using Leica SP5 confocal microscope and Imaris software. The liver size was examined by measuring the volume of EGFP expression. Ten embryos per experimental group were used and three independent replicates were performed. Scale bars, 100 μm; EGFP, enhanced green fluorescent protein; *P < 0.05, t-test.
fish and a 0.6-fold decrease in miR-145 mimic-injected fish (S1H Fig) . These results suggest that the mimic and inhibitor treatments specificity and efficiently modulate miR-145 expression. To study the influence of miR-145 in liver development, the 1.5 ng and 3 ng of control, miR-145 mimic or miR-145 inhibitor was injected into Tg(fabp10:EGFP) zebrafish. The Tg (fabp10:EGFP) is a transgenic fish that has liver-specific expression of enhanced green fluorescent protein (EGFP) at 36 hpf [29] . After miR-145 inhibitor and mimic injection, the dose- The expression patterns of miR-145 (A), grnA (B) and the hepatoblast-specific marker gene prox1 at 30, 50, 72 and 96 hpf were examined using FISH in wild-type zebrafish embryos. Scale bars, 25 μm (at 30 and 50 hpf), 50 μm (at 72 and 96 hpf). The dotted circles indicate prox1 positive cells that represent liver. Ten embryos per experimental group were used and three independent replicates were performed. (C) The fetal liver at 72 and 96 hpf were isolated to quantify liver specific expression patterns of miR-145 and GrnA. Fifteen fetal livers per experiment were used and three independent replicates were performed. The relative expression is normalized with internal control, U6 and ef1a expression.
dependent alteration of the size of liver expressing EGFP at 4 dpf was observed. The liver morphology in 3 ng miR-145 mimic and inhibitor treatment was significantly affected (S2 Fig). After 3ng miR-145 inhibitor injection, miR-145 inhibition significantly increased the size of liver expressing EGFP at 4 dpf (Fig 3B) . In contrast, embryos with overexpression of miR-145 exhibited smaller EGFP-expressing liver compared to that seen in control-injected liver ( Fig  3A and 3C) . The liver size was determined by measuring the volume of EGFP-expressing livers using three-dimensional confocal images (Fig 3D-3F) . At 4 dpf, the liver size of control mimic-injected Tg(fabp10:EGFP) embryos was 2.0 ± 0.5×10 and miR-145 mimic (C) injections in Tg(fabp10:EGFP) embryos. One hundred embryos per experimental group from one clutch were used and three independent replicates were performed. A 3D image of the liver was analyzed using Leica SP5 confocal microscope and Imaris software (D-F). The liver size was examined by measuring the volume of EGFP expression (G). Ten embryos per experimental group were used and three independent replicates were performed. The EGFP expression of Tg (fabp10:EGFP) fish showed an enlarged liver in miR-145 inhibitor-injected fish and an underdeveloped liver in miR-145 mimic-injected fish fish as compared to that in control fish. Scale bars, 100 μm; EGFP, enhanced green fluorescent protein; *P < 0.05, t-test. (Fig 3G) . These results indicate that miR-145 expression level negatively affects liver size at 4 dpf in zebrafish.
miR-145 is required for hepatic outgrowth during liver development
Whole-mount in situ hybridization (WISH) was used to clarify the stages of liver development affected by miR-145. We detected the gene expression of the liver specification marker hematopoietically expressed homeobox (hhex). The miR-145 inhibitor-and miR-145 mimicinjected embryos exhibited a normal expression pattern of hhex at 30 hpf (Fig 4A-4C) . The differentiation marker selenoprotein Pb (sePb) was detected at 50 hpf and also exhibited a normal expression pattern in miR-145 inhibitor-and miR-145 mimic-injected embryos as compared to those in controls (Fig 4D-4F) . At the later hepatic outgrowth stage, the prosperorelated homeobox 1 (prox1) and fatty acid-binding protein 10 (fabp10) were expressed in mature hepatocytes after 72 hpf. miR-145 inhibitor-injected embryos had increased prox1 expression and miR-145 mimic-injected embryos had reduced prox1 expression at 72 hpf ( Fig  4G-4I) . Furthermore, fabp10 expression also increased in miR-145 inhibitor-injected embryos at 96 hpf, while, inversely, fabp10 expression decreased in miR-145 mimic-injected embryos at 96 hpf (Fig 4J-4L) . The quantification of mRNA expression levels using qPCR revealed that hhex expression at 30 hpf and sePb expression at 50 hpf did not exhibit significant changes under miR-145 mimic and inhibitor administration. The proxl expression at 72 hpf and fabp10 expression at 96 hpf increased by 1.5-fold and 2.9-fold, respectively, in miR-145 inhibitorinjected embryos. Inversely, fabp10 expression at 96 hpf showed a 0.5-fold decrease in miR-145 mimic-injected embryos (Fig 4M) . In conclusion, these whole-mount and qPCR data indicate that miR-145 expression has major effects on hepatic outgrowth stage during liver development.
miR-145 influences hepatocyte proliferation in zebrafish embryos
To investigate whether miR-145 is involved in embryonic hepatic outgrowth through controlling cell proliferation, we performed immunohistochemistry with an antibody against proliferating cell nuclear antigen (PCNA) to observe cell proliferation in liver sections at 4 dpf in control mimic-, miR-145 mimic-and miR-145 inhibitor-injected fish. The percentage of PCNA-positive hepatocytes was increased by 2.4-fold in response to miR-145 inhibition in embryos at 4 dpf: 36.7 ± 6.7% in the control versus 90 ± 10% in the miR-145 inhibitor-injected fish (Fig 5E and 5G) . In contrast, the PCNA-positive hepatocytes of embryos with miR-145 overexpression showed a 1.8-fold reduction compared to those in controls at 4 dpf: 36.7 ± 6.7% in the control versus 20 ± 3.3% cells in miR-145 mimic-injected fish (Fig 5F and 5G) . These data suggest that miR-145 regulates cell proliferation and embryonic hepatic outgrowth. Consequently, miR-145 expression attenuates cell proliferation in embryonic liver.
miR-145 directly targets and modulates GrnA expression
To determine whether GrnA is a direct target of miR-145 in mediating hepatic outgrowth, we conducted bioinformatics software prediction using MicroInspector [26] and RNAhybrid [27] to identify the putative miR-145 recognition site located in exon 20 of the GrnA. First we made a construct containing the putative miR-145 recognition site behind a luciferase reporter (psi-grna vector, Fig 6A) . A mutant control was generated with the luciferase reporter vector followed by four nucleotides mutant at the putative miR-145 recognition site region. We cotransfected control mimic/miR-145 mimic and psi-grna / psi-grna mutant vector into the zebrafish liver cell line (ZFL cell line) for the luciferase assay. Luciferase activity was suppressed miR-145 mediates zebrafish hepatic outgrowth approximately 45% when miR-145 was co-expressed with the psi-grna vector, but there was no significant effect on the mutant control (Fig 6B) . These data suggest that miR-145 binds the The expression levels of hhex, sePb, prox1 and fabp10 were examined using qPCR (M). The ef1a expression level was served as an internal control (*P < 0.05, t-test). Twenty whole embryos per experimental group were used and three independent replicates were performed.
https://doi.org/10.1371/journal.pone.0177887.g004 miR-145 mediates zebrafish hepatic outgrowth putative miR-145 recognition site of GrnA in transfected ZFL cells. Furthermore, we determine whether endogenous GrnA expression is affected by miR-145. Control mimic, miR-145 inhibitor and miR-145 mimic were transfected into ZFL cells to assess the activation of GrnA and MET signaling using qPCR and Western blotting. At 24 hours after control mimic, miR-145 inhibitor and miR-145 mimic (100 nM) treatments in ZFL cells, the mRNA expression levels of GrnA and MET increased in ZFL cells treated with miR-145 inhibitor as compared to those in control-treated cells. In contrast, GrnA and MET were downregulated in miR-145-overexpressing ZFL cells (Fig 7A) . Therefore, after 48 hpf, the protein expression levels of inhibitor-and miR-145 mimic-injected fish were examined using PCNA staining at 4 dpf. The liver sections of three embryos per experimental group were used and three independent replicates were performed. miR-145 inhibitor-injected fish had more PCNA-positive hepatocytes (B, E) as compared to those in control (A,D). In contrast, a low signal was detected in response to miR-145 mimic treatment (C,F). The arrowhead indicates PCNA-positive hepatocytes. The percentage of PCNA-positive hepatocytes was counted (G). The blue staining is hematoxylin stain; I, intestine; L, liver; Scale bars, 20 μm; *P < 0.05, t-test.
https://doi.org/10.1371/journal.pone.0177887.g005
miR-145 mediates zebrafish hepatic outgrowth
GrnA and MET were further examined using Western blotting. Following miR-145 inhibition, the results showed that GrnA and MET protein expression levels increased by 1.2-fold and 1.5-fold, respectively, as compared to those in control mimic treatment in ZFL cells. In contrast, GrnA and MET protein expression levels reduced by 0.7-fold and 0.4-fold, respectively, in miR-145-overexpressing ZFL cells as compared with those in control mimic-treated cells (Fig 7B) . These data suggest that miR-145 modulates GrnA expression through binding to GrnA mRNA in zebrafish liver.
GrnA can rescue the defect in liver outgrowth in miR-145 morphants
To determine whether miR-145 affects embryonic hepatic outgrowth through targeting GrnA, we performed GrnA mRNA and morpholino rescue experiments to verify whether GrnA signaling can rescue the miR-145-induced liver defect. miR-145 knockdown resulted in a Fig 6. miR-145 directly targets grnA as determined by luciferase assay. The predicted miR-145 target site on GrnA CDS is illustrated. WT and mutant forms of GrnA CDS were constructed in psi-check2 reporter vector (A). miR-145 mimic and psi-grna-WT/psi-grna-mutant vector were co-transfected into ZFL cells for the luciferase assay. The luciferase activity of psi-grna-WT was suppressed approximately 45% in response to miR-145 mimic treatment. In contrast, the luciferase activity of psi-grna-mutant was unchanged in response to miR-145 mimic treatment (*P < 0.05, t-test) (B). Three independent replicates were performed.
https://doi.org/10.1371/journal.pone.0177887.g006 miR-145 mediates zebrafish hepatic outgrowth significant increase in liver size at 96 hpf in Tg(fabp10: EGFP) fish (Fig 8C) . Co-injection of the miR-145 inhibitor with 0.25 ng/embryo GrnA morpholino in Tg(fabp10: EGFP) embryos restored normal liver size (Fig 8E) . Smaller liver sizes were observed at 96 hpf in miR-145 overexpressing-Tg(fabp10: EGFP) fish (Fig 8D) . We co-injected miR-145 mimic and 0.4 ng/embryo GrnA mRNA into Tg(fabp10: EGFP) embryos and observed that the liver size was restored to normal (Fig 8F) compared to that in the control at 96 hpf (Fig 8B) . The quantification of liver volume showed enlarged liver (3.4± 0.6×10 (Fig 8G) . In addition, the GrnA mRNA and morpholino rescued the liver size in a dose-dependent manner (S4 Fig). These results suggest that miR-145 modulates embryonic liver outgrowth through regulating GrnA signaling. The expression levels of the grnA and met genes were examined using qPCR after 24 hours of control, miR-145 mimic and miR-145 inhibitor treatment in ZFL cells (A). The protein levels of GrnA, MET and GAPDH were examined by Western blotting in ZFL cells at 48 hours after control, miR-145 mimic and miR-145 inhibitor treatments. The relative GrnA, MET and GAPDH protein levels were quantified as shown in the low panel (*P < 0.05, t-test) (B). Three independent replicates were performed.
https://doi.org/10.1371/journal.pone.0177887.g007 miR-145 mediates zebrafish hepatic outgrowth
Discussion
The regulatory mechanisms of liver development are complex, and involve in many growth factors and transcription factors across three stages-hepatic specification, differentiation and outgrowth. The miRNAs are known to be important genetic regulators in development. A liver specific miRNA, miR-122a, has been reported to control hepatocyte differentiation [30] . Besides miR-122a, little is known about the function of other miRNAs involved in liver development. Researchers have generated liver-specific DICER1 knockout mice to prove that the loss of miRNAs increases liver cell proliferation. However, the fact that which miRNAs participate in embryonic liver cell proliferation remains unclear. In a previous study, PGRN is a pleiotropic autocrine growth factor that was found to be essential for hepatic outgrowth through transcriptional regulation of MET during liver development [16] . Therefore, we are . Thirty embryos per experimental group were used and three independent replicates were performed. A 3D image of the liver was observed using Leica SP5 confocal microscope and Imaris software. The liver size was examined by measuring the volume of EGFP expression (G). Ten embryos per experimental group were used and three independent replicates were performed. Scale bars, 100 μm; EGFP, enhanced green fluorescent protein; *P < 0.05, t-test.
interested in exploring the fine-tuning regulator on PGRN signaling involved in embryonic liver growth. We identified several miRNAs from the miRNA predictions of zebrafish GrnA. Because the 3'UTR of GrnA is 487 nucleotides in size, there are only putative four miRNAs, including miR-9, miR-206, miR-731 and miR-217 predicted by TargetScan. In this study, we first showed the dysregulation of four miRNAs couldn't influence liver development. The miR-9 is abundantly expressed in developing neurogenic cell that regulates neuron differentiation [31] . The miR-206 is a muscle specific miRNA participating in myogenesis [32] . The miR-217 is expressed in the pancreas [33] . The miR-731 is induced by hypoxic stress [34] . Hence, the four miRNAs may not regulate liver development. We demonstrate that miR-145, which targets the CDS region of GrnA, can affect embryonic liver growth. The expression pattern of miR-145, especially in the embryonic liver, has not been confirmed. We also demonstrate an inverse correlation between miR-145 and GrnA expression during hepatogenesis. miR-145 expression in the liver primordium decreases from 30 to 96 hpf and GrnA expression increases from 30 to 96 hpf. The expression pattern of GrnA is similar to that previously reported [35] . miR-145 is expressed in liver of zebrafish embryos at 30 hpf. miR-145 is ubiquitously expressed at 19-somite zebrafish embryos as demonstrated by Zeng et al. [28] . Furthermore, we show that miR-145 is almost not expressed in zebrafish embryos at 96 hpf. Wienholds's and Zeng's groups have proved that miR-145 is expressed in gut but not in liver of zebrafish embryos at 96 hpf [28, 33] . Moreover, GrnA is widely expressed in many other tissues. Its expression increases from 24 to 96 hpf [35] .
Numerous reports have indicated that miR-145 is a suppressor of tumor cell proliferation in various types of cancers [36] [37] [38] [39] , including liver cancer [40] . The mechanisms of tumorigenesis have been shown to be associated with the dysregulation of embryonic signaling pathways. Although miR-145 has been shown to be involved in liver cancer progression, the functional roles of miR-145 in embryonic liver development are still unknown. This study is the first to show that the manipulation of miR-145 expression affects embryonic liver size. Expression of certain specific markers at different liver developmental stages is affected by miR-145. However, the expression of hhex, a marker for liver specification, is affected neither by the loss of miR-145 nor by miR-145 overexpression. At liver budding stages, sePb expression is also not significantly altered. In contrast, at hepatic outgrowth stages, loss of miR-145 increases prox1 and fabp10 expression, while overexpression of miR-145 decreases prox1 and fabp10 expression. We show that manipulation of miR-145 has minor effects on the expression of specification-and differentiation-related genes. However, we cannot exclude the possibilities of miR-145 involvement in hepatic specification and/or differentiation. We hypothesize that hepatocyte outgrowth is the major target of miR-145 during liver development and that the process of hepatic proliferation is activated in the outgrowth stages. We reason that loss or attenuation of miR-145 expression promotes hepatic proliferation and liver outgrowth, and inversely, miR-145 overexpression suppresses hepatic proliferation and liver growth. Interestingly, miR-145 expression is downregulated in liver cancer, and restoration of miR-145 expression in liver tumor cells results in inhibition of proliferation in these cells [21, 22] . Our results suggest that the relevant mechanisms of miR-145-mediated growth regulation may exist in both embryonic hepatic growth and liver tumor growth.
In this study, we decide to determine whether the direct target gene of the miRNA is useful for studying the biological function of miR-145 during liver development. The seed sequence between the 5' end of the microRNA and the mRNA is a critical determinant of the potential binding site. Usually, a perfect or near perfect match of the seed sequence between miRNA and mRNA targets will lead to mRNA degradation [41] . We have found that the coding region of GrnA has a near perfect complementary binding site for the miR-145 seed region. Furthermore, in humans, PGRN is also a predicted target of miR-145. It is possible that the miR-145 miR-145 mediates zebrafish hepatic outgrowth and PGRN regulatory mechanism is conserved. Importantly, the results of the luciferase activity assay suggest that miR-145 directly targets GrnA. In a previous study, GrnA is shown to be essential for hepatic outgrowth through transcriptional regulation of MET during liver development [16] . Our findings reveal that the mRNA and protein expression levels of GrnA are inversely regulated in response to the loss and overexpression of miR-145. At the same time, MET gene is also inversely regulated by miR-145. In the rescue experiments, we show that GrnA expression rescues the hepatic outgrowth defect caused by miR-145 manipulation. Consequently, we show that miR-145 may serve as a novel regulator of GrnA to modulate hepatic outgrowth. Our results indicate an important role of miR-145 in modulating hepatic outgrowth.
In addition, we find an inverse correlation between miR-145 downregulation and GrnA overexpression in zebrafish liver outgrowth. Similar gene expression patterns of miR-145 and PGRN also occur in pathological liver growth. miR-145 downregulation and PGRN overexpression are required for liver tumor cell proliferation. PGRN is a growth factor and has been reported to be associated with the tumor growth of many cancers, such as breast [42] , ovary [43] , liver [14] , kidney [44] and bile duct carcinomas [45] . PGRN overexpression promotes tumor cell growth through MEK/Erk and PI3K/Akt signaling activation [46] . In addition, our previous study shows that GrnA regulates Erk signaling through transcriptional activation of MET in zebrafish liver outgrowth [16] . miR-145 is downregulated and serves as a tumor suppressor microRNA in many types of cancers, such as breast [47] , ovary [48] , liver [19] and colon cancers [49] . In tumor growth, restoration of miR-145 inhibits the PI3K/Akt pathway and suppresses cell growth [50] . miR-145 also reduces MEK/Erk signaling in tumor cells [51] . Taken together, these results suggest that miR-145 and PGRN regulate the same downstream signaling pathways-the MEK/Erk and PI3K/Akt pathways. In this study, we show that miR-145 targets GrnA in attenuating zebrafish liver outgrowth. For further study, we propose that miR-145 targeting of PGRN may contribute to tumor cell growth in cancer progression.
Taken together, we identify a new role of miR-145 that is required for hepatic outgrowth through regulating GrnA expression. Moreover, we provide a zebrafish model that could be used to study the regulatory mechanisms of miRNAs and their target mRNAs during liver development. The regulatory mechanism of miR-145 and GrnA is important not only in physiological liver growth but also in pathological liver growth. This mechanism may be a new therapeutic target for liver cancer. Fig. The developmental growth is normal under altered expression of miR-145 . Two mesodermal genes, heart and neural crest derivatives expressed transcript 2 (hand2) at 30 hpf and myogenic differentiation 1(myod) at 54 hpf was examined using WISH. The result reveals mesoderm development was not significantly affected by manipulation of miR-145 expression (A). The body length were measured at 96 hpf after control mimic, miR-145 inhibitor, miR-145 mimic injection in Tg(fabp10:EGFP) embryos (B). (Scale bars, 0.50 mm; thirty embryos per experimental group were used and three independent replicates were performed). 
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